Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer
BUZZ-Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer ** Shares of Nanjing Leads Biolabs 9887.HK rise 6.1% to HK$56.65, on course for the biggest one-day pct gain since July 15
** Stock touches the highest level since July 28 in the second session of gain
** China-based oncology therapies developer says National Medical Products Administration (NMPA) has approved the Investigational New Drug (IND) application of its drug candidate LBL-024 (Opamtistomig, a PD-L1/4-1BB bispecific antibody) for the treatment of metastatic colorectal cancer
** This milestone marks an important step in expanding the indications of LBL-024 into gastrointestinal cancers, extending its immuno-oncology portfolio from biliary tract cancer, gastric cancer, and esophageal squamous cell carcinoma to colorectal cancer - co
** YTD, stock up 11.1%, while Hang Seng Biotech Index .HSBIO down 3.2%
(Reporting by Donny Kwok)
Recent news on Nanjing Leads Biolabs
See all newsBrief: Nanjing Leads Biolabs Says FDA Grants Fast Track Designation To LBL-024
Brief: Nanjing Leads Biolabs Posts HY Loss Attributable RMB221.9 Million
Nanjing Leads rises on clinical study progress on cancer treatment drug
Nanjing Leads Biolabs jumps on progress of tumor antibody treatment
Nanjing Leads Biolabs rises on NMPA's IND approval for colorectal cancer